U
AH

UBS’s Accretive Health AH Stock Holding History

UBS’s Portfolio AH Stock Details AH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-5,000
Closed -$40K – 11391
2014
Q1 		$40K Buy
5,000
+2,300
+85% +$20.4K ﹤0.01% 7162
2013
Q4 		$25K Sell
2,700
-4,000
-60% -$34.4K ﹤0.01% 7899
2013
Q3 		$61K Buy
6,700
+3,300
+97% +$32.8K ﹤0.01% 6617
2013
Q2 		$37K Buy
+3,400
New +$35.8K ﹤0.01% 7146

Other funds holding AH

JRP
Jasper Ridge Partners Menlo Park, California $4.49B AUM 18.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
RMC
Regis Management Company Menlo Park, California $331M AUM 14.13% 1-Year Est. Return
BCM
Breithorn Capital Management New York $141M AUM 41.82% 1-Year Est. Return
ECM
EII Capital Management New York $774K AUM 22.41% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
MIM
Merion Investment Management Bay Harbor Islands, Florida $1.26M AUM 28.57% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
SCM
Stonebridge Capital Management Los Angeles, California $220M AUM

UBS's AH Position: Q2 2014 in Review

UBS sold out of Accretive Health (AH) in Q2 2014, closing a stake of 13,479 shares — an estimated $107K sold.

UBS first reported a position in AH in Q2 2013 and held it in 4 quarters. The position peaked at $1.57M in Q2 2013. 12 funds tracked by Wall St. Rank hold AH as of Q2 2014.

  • UBS reported no remaining Accretive Health position as of Q2 2014 after selling out during the quarter.
  • UBS sold 13,479 Accretive Health shares in Q2 2014, an estimated $107K.
  • UBS first reported a position in Accretive Health in Q2 2013 and held it in 4 quarters.
  • UBS's Accretive Health position peaked at $1.57M in Q2 2013.
  • 12 funds tracked by Wall St. Rank held Accretive Health as of Q2 2014.

Based on UBS's 13F filing for Q2 2014, filed 14 Aug 2014.